<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Autonomix Medical, Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/autonomix-medical-inc-common-stock</link>
<description>Latest news and press releases for Autonomix Medical, Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 12:45:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/autonomix-medical-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683545e478dffbe2df0e2bfa.webp</url>
<title>Autonomix Medical, Inc. Common Stock</title>
<link>https://6ix.com/company/autonomix-medical-inc-common-stock</link>
</image>
<item>
<title>Autonomix Medical Announces Abstract Acceptance at Digestive Disease Week 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation</title>
<link>https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-announces-abstract-acceptance-at-digestive-disease-week-2026-showcasing-long-term-data-in-pancreatic-cancer-pain-mitigation</link>
<guid isPermaLink="true">https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-announces-abstract-acceptance-at-digestive-disease-week-2026-showcasing-long-term-data-in-pancreatic-cancer-pain-mitigation</guid>
<pubDate>Wed, 29 Apr 2026 12:45:00 GMT</pubDate>
<description>THE WOODLANDS, TX, April 29, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced its long-term data titled “Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation” has been accepted for presentation at Digestive Disease Week 2026 (DDW 2026), being held May 2–5, 2026, in Chicago, IL an</description>
</item>
<item>
<title>Autonomix Medical to Present Long-Term Pain Mitigation Data in Pancreatic Cancer at ECIO 2026</title>
<link>https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-to-present-long-term-pain-mitigation-data-in-pancreatic-cancer-at-ecio-2026</link>
<guid isPermaLink="true">https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-to-present-long-term-pain-mitigation-data-in-pancreatic-cancer-at-ecio-2026</guid>
<pubDate>Wed, 22 Apr 2026 12:42:00 GMT</pubDate>
<description>THE WOODLANDS, TX, April 22, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that new long-term clinical data evaluating its transvascular radiofrequency (RF) ablation approach for pain mitigation in pancreatic adenocarcinoma will be presented at the European Conference on Interventional Oncology (ECIO) 2026 being held April 26 – 30, 2026 in Basel C</description>
</item>
<item>
<title>Autonomix Medical Selected for Featured Abstract and Podium Presentation of Long-Term Pain Mitigation in Pancreatic Cancer at SIR 2026</title>
<link>https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-selected-for-featured-abstract-and-podium-presentation-of-long-term-pain-mitigation-in-pancreatic-cancer-at-sir-2026</link>
<guid isPermaLink="true">https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-selected-for-featured-abstract-and-podium-presentation-of-long-term-pain-mitigation-in-pancreatic-cancer-at-sir-2026</guid>
<pubDate>Wed, 08 Apr 2026 12:40:00 GMT</pubDate>
<description>THE WOODLANDS, TX, April 08, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that its abstract titled, “Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation,” has been selected as a Featured Abstract for podium presentation at the Society of Interventional Radiology (SIR) 2026 A</description>
</item>
<item>
<title>Autonomix Medical to Present at LSI USA ’26</title>
<link>https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-to-present-at-lsi-usa-26-1</link>
<guid isPermaLink="true">https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-to-present-at-lsi-usa-26-1</guid>
<pubDate>Wed, 11 Mar 2026 12:40:00 GMT</pubDate>
<description>THE WOODLANDS, TX, March 11, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that Brad Hauser, President and Chief Executive Officer of Autonomix will present at LSI USA ’26 on Tuesday, March 17, 2026 at 9:15 AM PT. In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of</description>
</item>
<item>
<title>Autonomix Medical Selected for Best Innovation Competition at CRT 2026</title>
<link>https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-selected-for-best-innovation-competition-at-crt-2026-28</link>
<guid isPermaLink="true">https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-selected-for-best-innovation-competition-at-crt-2026-28</guid>
<pubDate>Thu, 05 Mar 2026 13:45:00 GMT</pubDate>
<description>THE WOODLANDS, TX, March 05, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that its presentation titled, “Illuminating The Nervous System With Transvascular Precision-guided Technology,” has been selected for oral presentation in the Best Innovation Competition at Cardiovascular Research Technologies (CRT) 2026. The presentation will be delivered</description>
</item>
<item>
<title>Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis</title>
<link>https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis</link>
<guid isPermaLink="true">https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis</guid>
<pubDate>Wed, 04 Mar 2026 13:40:00 GMT</pubDate>
<description>THE WOODLANDS, TX, March 04, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that Nikola Cesarovic, PhD, will present clinical feasibility and outcome data at the Cardiovascular Research Technologies (CRT) 2026 Meeting, happening March 7-10, 2026, in Washington, DC. The abstract titled, “Novel Technique For Transvascular Peripheral Nerve Neurolysis</description>
</item>
<item>
<title>Autonomix Medical Announces Release of New CEO Corner Segment Highlighting Publication Strategy and Scientific Validation</title>
<link>https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-announces-release-of-new-ceo-corner-segment-highlighting-publication-strategy-and-scientific-validation</link>
<guid isPermaLink="true">https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-announces-release-of-new-ceo-corner-segment-highlighting-publication-strategy-and-scientific-validation</guid>
<pubDate>Wed, 25 Feb 2026 13:30:00 GMT</pubDate>
<description>CEO, Brad Hauser, discusses building clinical credibility through rigorous science and peer-reviewed engagement THE WOODLANDS, TX, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the release of its latest CEO Corner segment featuring President and Chief Executive Officer, Brad Hauser. As part of the segment, Mr. Hauser discusses Autonomix’s</description>
</item>
<item>
<title>Autonomix Medical Selected to Present New Long-Term Pain Mitigation Data in Pancreatic Cancer at SSO 2026 Annual Meeting in Podium Presentation</title>
<link>https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-selected-to-present-new-long-term-pain-mitigation-data-in-pancreatic-cancer-at-sso-2026-annual-meeting-in-podium-presentation</link>
<guid isPermaLink="true">https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-selected-to-present-new-long-term-pain-mitigation-data-in-pancreatic-cancer-at-sso-2026-annual-meeting-in-podium-presentation</guid>
<pubDate>Thu, 19 Feb 2026 13:30:00 GMT</pubDate>
<description>THE WOODLANDS, TX, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that Clarke Wilkirson, PhD, Clinical Development Engineer II, will present new long-term clinical data at the Society of Surgical Oncology (SSO) 2026 Annual Meeting, happening March 5-7, 2026, in Phoenix, Arizona. The presentation, titled “Pain Mitigation in Pancreatic Adeno</description>
</item>
<item>
<title>Autonomix Medical to Present Final Analysis on Pain Mitigation in Pancreatic Cancer at SIO 2026 Annual Scientific Meeting</title>
<link>https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-present-final-analysis-133000784</link>
<guid isPermaLink="true">https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-present-final-analysis-133000784</guid>
<pubDate>Wed, 28 Jan 2026 13:30:00 GMT</pubDate>
<description>THE WOODLANDS, TX, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that final clinical data evaluating its transvascular radiofrequency (RF) ablation approach for pain mitigation in pancreatic adenocarcinoma will be presented at the Society of Interventional Oncology (SIO) 2026 Annual Scientific Meeting happening February 4-8, 2026 in Savan</description>
</item>
<item>
<title>Autonomix Showcases Compelling PoC Study Clinical Data Showing Rapid and Durable Pain Relief Across All Disease Stages of Pancreatic Cancer at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium</title>
<link>https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-showcases-compelling-poc-study-134500851</link>
<guid isPermaLink="true">https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-showcases-compelling-poc-study-134500851</guid>
<pubDate>Fri, 09 Jan 2026 13:45:00 GMT</pubDate>
<description>New subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, including late-stage patients with otherwise limited treatment options THE WOODLANDS, TX, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced new subgroup clinical data from its PoC study presented at the 2026 ASCO Gastroi</description>
</item>
<item>
<title>Autonomix Medical, Inc. Granted European Patent on Platform Technology Enabling Precision Nerve-Targeted Therapies in Cardiology</title>
<link>https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-inc-granted-european-133000593</link>
<guid isPermaLink="true">https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-inc-granted-european-133000593</guid>
<pubDate>Tue, 30 Dec 2025 13:30:00 GMT</pubDate>
<description>With over 80 issued patents and 39 pending patent applications, Autonomix is building a comprehensive, global IP portfolio in nerve-sensing and modulation Newly granted patent further strengthens the Company’s strategic position in a multi-billion-dollar market opportunity, unlocking potential across cardiovascular, renal, and other high-burden diseases THE WOODLANDS, TX, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device com</description>
</item>
<item>
<title>Autonomix Medical, Inc. (NASDAQ: AMIX) Highlights Expanding IP Portfolio and Multi-Indication Platform Strategy in Virtual Investor CEO Connect Segment</title>
<link>https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-inc-nasdaq-amix-134500958</link>
<guid isPermaLink="true">https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-inc-nasdaq-amix-134500958</guid>
<pubDate>Tue, 23 Dec 2025 13:45:00 GMT</pubDate>
<description>Access the segment here THE WOODLANDS, TX, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it recently participated in a Virtual Investor CEO Connect segment. As part of the segment, Brad Hauser, CEO of Autonomix, outlined two key priorities shaping the Company’s trajectory: strengthening its platform through intellectual property protectio</description>
</item>
<item>
<title>Autonomix Medical, Inc. Announces Abstract Selected for Poster Presentation at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium</title>
<link>https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-inc-announces-abstract-133000146</link>
<guid isPermaLink="true">https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-inc-announces-abstract-133000146</guid>
<pubDate>Thu, 18 Dec 2025 13:30:00 GMT</pubDate>
<description>THE WOODLANDS, TX, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced its abstract has been accepted for poster presentation at the 2026 ASCO Gastrointestinal Cancers Symposium, being held January 8-10, 2026 in San Francisco, CA. Details of the poster presentation are as follows: Title: Pain mitigation in pancreatic adenocarcinoma: A long-term</description>
</item>
<item>
<title>Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment Highlighting Continued Execution and Strategic Growth</title>
<link>https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-inc-nasdaq-amix-134500269</link>
<guid isPermaLink="true">https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-inc-nasdaq-amix-134500269</guid>
<pubDate>Wed, 26 Nov 2025 13:45:00 GMT</pubDate>
<description>THE WOODLANDS, TX, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the next CEO Corner segment has been published on the Company’s website. For the segment, Brad Hauser, President and CEO of Autonomix, discussed two key areas that are shaping the Company’s path forward: protecting the strength of its platform through intellectual property,</description>
</item>
<item>
<title>Autonomix Medical, Inc. Announces Pricing of $5.0 Million Private Placement Priced At The Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-inc-announces-pricing-133000196</link>
<guid isPermaLink="true">https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-inc-announces-pricing-133000196</guid>
<pubDate>Tue, 18 Nov 2025 13:30:00 GMT</pubDate>
<description>THE WOODLANDS, TX, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 4,501,666 shares of common stock (or pre-funded warrants in-lieu thereof), and together with unregistered Series C warrants to purchase up to an aggregate 9,003,332 shar</description>
</item>
<item>
<title>Autonomix Medical, Inc. Reports Positive Subgroup Results Demonstrating Sustained Improvements in Quality of Life from Post Hoc Analysis of Pancreatic Cancer PoC Study</title>
<link>https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-inc-reports-positive-130000978</link>
<guid isPermaLink="true">https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-inc-reports-positive-130000978</guid>
<pubDate>Mon, 17 Nov 2025 13:00:00 GMT</pubDate>
<description>EORTC QLQ-C30 subgroup results confirm broad and durable quality-of-life improvements across disease stages and metastasis status, complementing previously reported pain reduction and opioid-free outcomes Late-stage patients showed substantial improvements, suggesting ablation provided clinically meaningful changes even in advanced severe disease THE WOODLANDS, TX, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company de</description>
</item>
<item>
<title>Autonomix Medical, Inc. Featured in Two Innovation in Interventional Cardiology Podium Presentations at the Transcatheter Cardiovascular Therapeutics® (TCT®) Annual Scientific Conference</title>
<link>https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-inc-featured-two-130000977</link>
<guid isPermaLink="true">https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-inc-featured-two-130000977</guid>
<pubDate>Fri, 24 Oct 2025 13:00:00 GMT</pubDate>
<description>THE WOODLANDS, TX, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it will be featured in two podium presentations at the Transcatheter Cardiovascular Therapeutics® (TCT®) Annual Scientific Conference (TCT 2025) being held October 25-28, 2025 in San Francisco, CA. The presentations will highlight positive results from the initial phase of A</description>
</item>
<item>
<title>Autonomix Medical, Inc. to Highlight Innovative Nerve-Sensing and Ablation Platform at the 2025 Maxim Growth Summit</title>
<link>https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-inc-highlight-innovative-131500707</link>
<guid isPermaLink="true">https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-inc-highlight-innovative-131500707</guid>
<pubDate>Thu, 16 Oct 2025 13:15:00 GMT</pubDate>
<description>THE WOODLANDS, TX, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it will participate at the 2025 Maxim Growth Summit, taking place October 22-23, 2025 in New York, NY. This prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries. As pa</description>
</item>
<item>
<title>Autonomix Medical, Inc. Granted U.S. Patent on Platform Technology Enabling Precision Nerve-Targeted Therapies in Cardiology</title>
<link>https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-inc-granted-u-124500935</link>
<guid isPermaLink="true">https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-inc-granted-u-124500935</guid>
<pubDate>Thu, 09 Oct 2025 12:45:00 GMT</pubDate>
<description>With over 120 issued and pending patent applications, Autonomix is building a comprehensive, global IP portfolio in nerve-sensing and modulation Newly issued patent strengthens the Company’s strategic position in a multi-billion-dollar market opportunity and unlocking potential across cardiovascular, renal, and other high-burden diseases THE WOODLANDS, TX, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated t</description>
</item>
<item>
<title>Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment</title>
<link>https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-inc-announces-release-124500447</link>
<guid isPermaLink="true">https://6ix.com/company/autonomix-medical-inc-common-stock/news/autonomix-medical-inc-announces-release-124500447</guid>
<pubDate>Thu, 02 Oct 2025 12:45:00 GMT</pubDate>
<description>THE WOODLANDS, TX, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Brad Hauser, CEO of Autonomix, discusses the Company’s recently announced longer-term post hoc analysis from its first-in-human proof-of-concept study (“PoC 1”) and recent pr</description>
</item>
</channel>
</rss>